Modification: BACE1: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: N/A
Genetic Background: C57BL
Availability: No longer available through Michael Willem
Transgene expressing wild-type human BACE1 driven by the mouse Thy1 promoter.
Transgene is expressed in neurons only. No change in the processing of endogenous murine APP.
This mouse was used to generate a double-transgenic by breeding to mice overexpressing human APP with the London mutation (V717I) driven by the mouse thy1 promoter. The APP(V717I) single transgenics develop widespread amyloid plaques in brain parenchyma as well as cerebral amyloid angiopathy, and BACE1 expression increased the number of amyloid plaques in the double-transgenic mice. In contrast, vascular amyloid deposition was lower in the double-transgenic mice relative to sex- and age-matched APP(V717I) single transgenics (Willem et al., 2004).
Last Updated: 15 Nov 2013
- Willem M, Dewachter I, Smyth N, Van Dooren T, Borghgraef P, Haass C, Van Leuven F. beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol. 2004 Nov;165(5):1621-31. PubMed.
No Available Further Reading